Calidi Biotherapeutics Announces Immediate Exercise Of Certain Outstanding Series B And C Warrants To Purchase Up To An Aggregate Of 10,698,000 Shares Of Common Stock At A Reduced Exercise Price Of $0.20; To Generate ~$2.1M In Gross Proceeds
Portfolio Pulse from Benzinga Newsdesk
Calidi Biotherapeutics has announced an agreement to immediately exercise 10.7 million warrants, reducing the exercise price to $0.20. This exercise is expected to generate approximately $2.1 million in gross proceeds.
May 31, 2024 | 12:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Calidi Biotherapeutics has announced an agreement to immediately exercise 10.7 million warrants at a reduced price of $0.20, expected to generate $2.1 million in gross proceeds.
The immediate exercise of 10.7 million warrants at a reduced price will provide Calidi Biotherapeutics with $2.1 million in gross proceeds. This influx of capital is likely to be viewed positively by investors, potentially leading to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100